Targeting the trimolecular complex: The pathway towards type 1 diabetes prevention

Diabetes Technology and Therapeutics

Volumn 15, Issue SUPPL.2, 2013, Pages

  Michels, Aaron W ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; INSULIN; PEPTIDE; T LYMPHOCYTE RECEPTOR; ANTIDIABETIC AGENT; AUTOANTIBODY; AUTOANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; DIABETES MELLITUS; GENOTYPE; HUMAN; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; AUTOIMMUNE DISEASE; DIABETES MELLITUS, TYPE 1; DISEASE COURSE; FEMALE; GENETIC PREDISPOSITION; GENETICS; HISTORY; IMMUNOLOGY; MALE; METABOLISM;

AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; RECEPTORS, ANTIGEN, T-CELL;

EID: 84895852712     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0114     Document Type: Article

References (46)

1. Eisenbarth GS: Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986;314:1360-1368.
2. Todd JA: Etiology of type 1 diabetes. Immunity 2010;32:457-467.
3. Bluestone JA, Herold K, Eisenbarth G: Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010;464:1293-1300.
4. Harjutsalo V, Podar T, Tuomilehto J: Cumulative incidence of type 1 diabetes in 10,168 siblings of Finnish young-onset type 1 diabetic patients. Diabetes 2005;54:563-569.
5. Harjutsalo V, Sjoberg L, Tuomilehto J: Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008;371:1777-1782. (Pubitemid 351697953)
6. Bluestone JA, Mackay CR, O'Shea JJ, Stockinger B: The functional plasticity of T cell subsets. Nat Rev Immunol 2009;9:811-816.
7. Michels AW, Nakayama M: The anti-insulin trimolecular complex in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2010;17:329-334.
8. Eisenbarth GS: Banting Lecture 2009: an unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes 2010;59:759-774.
9. Eisenbarth GS, Wilson P, Ward F, Lebovitz HE: HLA type and occurrence of disease in familial polyglandular failure. N Engl J Med 1978;298:92-94. (Pubitemid 8260219)
10. Baschal EE, Eisenbarth GS: Extreme genetic risk for type 1A diabetes in the post-genome era. J Autoimmun 2008;31:1-6.
11. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, Mychaleckyj JC, Todd JA, Bonella P, Fear AL, Lavant E, Louey A, Moonsamy P; Type 1 Diabetes Genetics Consortium: HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the Type 1 Diabetes Genetics Consortium Families. Diabetes 2008;57:1084-1092.
12. Concannon P, Rich SS, Nepom GT: Genetics of type 1A diabetes. N Engl J Med 2009;360:1646-1654.
13. Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-229. (Pubitemid 32718550)
14. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz DA, Palmer JP, Eisenbarth GS: Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 2003;88:103-108. (Pubitemid 36115150)
15. Nakayama M, Eisenbarth GS: Paradigm shift or shifting paradigm for type 1 diabetes. Diabetes 2012;61:976-978.
16. Eisenbarth GS: Prevention of type 1A diabetes mellitus. Endocr Pract 2012;18:745-749.
17. Sosinowski T, Eisenbarth GS: Type 1 diabetes: primary antigen/peptide/register/trimolecular complex. Immunol Res 2013;55:270-276.
18. Michels AW, Eisenbarth GS: Immune intervention in type 1 diabetes. Semin Immunol 2011;23:214-219.
19. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC: The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-17045. (Pubitemid 350210987)
20. Nikolaeva N, Bemelman FJ, Yong SL, van Lier RAW, ten Berge IJM: Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation 2006;81:445-454. (Pubitemid 43255733)
21. Yu L, Miao D, Scrimgeour L, Johnson K, Rewers M, Eisenbarth GS: Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 2012;61: 179-186.
22. Diabetes Prevention Trial-Type 1 Diabetes Study Group: Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691.
23. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E: Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-1076. (Pubitemid 40616615)
24. Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP: Long-term outcome of individuals treated with oral insulin: Diabetes Prevention TrialType 1 (DPT-1) oral insulin trial. Diabeset Care 2011;34:1585-1590.
25. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, Eisenbarth GS: Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005;435:220-223. (Pubitemid 40685949)
26. Nakayama M, Beilke JN, Jasinski JM, Kobayashi M, Miao D, Li M, Coulombe MG, Liu E, Elliott JF, Gill RG, Eisenbarth GS: Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J Clin Invest 2007;117:1835-1843. (Pubitemid 47036317)
27. Liu E, Yu L, Moriyama H, Eisenbarth GS: Animal models of insulin-dependent diabetes. Methods Mol Med 2004;102:195-212.
28. Steck AK, Johnson K, Barriga KJ, Miao D, Yu L, Hutton JC, Eisenbarth GS, Rewers MJ: Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: Diabetes Autoimmunity Study in the Young. Diabetes Care 2011;34:1397-1399.
29. Parikka V, Nanto-Salonen K, Saarinen M, Simell T, Ilonen J, Hyo ty H, Veijola R, Knip M, Simell O: Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012;55:1926-1936.
30. Roep BO, Buckner J, Sawcer S, Toes R, Zipp F: The problems and promises of research into human immunology and autoimmune disease. Nat Med 2012;18:48-53.
31. Stadinski B, Kappler J, Eisenbarth GS: Molecular targeting of islet autoantigens. Immunity 2010;32:446-456.
32. Stadinski BD, Zhang L, Crawford F, Marrack P, Eisenbarth GS, Kappler JW: Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci U S A 2010;107:10978-10983.
33. Crawford F, Stadinski B, Jin N, Michels A, Nakayama M, Pratt P, Marrack P, Eisenbarth G, Kappler JW: Specificity and detection of insulin-reactive CD4 + T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc Natl Acad Sci U S A 2011;108:16729-16734.
34. Mohan JF, Levisetti MG, Calderon B, Herzog JW, Petzold SJ, Unanue ER: Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat Immunol 2010;11:350-354.
35. Michels AW, Ostrov DA, Zhang L, Nakayama M, Fuse M, McDaniel K, Roep BO, Gottlieb PA, Atkinson MA, Eisenbarth GS: Structure-based selection of small molecules to alter allele-specific MHC Class II antigen presentation. J Immunol 2011;187:5921-5930.
36. Battaglia M, Gregori S, Bacchetta R, Roncarolo MG: Tr1 cells: from discovery to their clinical application. Semin Immunol 2006;18:120-127. (Pubitemid 43248740)
37. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50. (Pubitemid 44116698)
38. Michels AW: Targeting the trimolecular complex. Clin Immunol 2013 March 5 [Epub ahead of print]. pii: S1521-6616(13)00058-2. doi: 10.1016/j.clim.2013.02. 020.
39. Zhang L, Stadinski BD, Michels A, Kappler JW, Eisenbarth GS: Immunization with an insulin peptide-MHC complex to prevent type 1 diabetes of NOD mice. Diabetes Metab Res Rev 2011;27:784-789.
40. Michels AW, von Herrath M: 2011 update: antigen-specific therapy in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2011;18:235-240.
41. Liu E, Abiru N, Moriyama H, Miao D, Eisenbarth GS: Induction of insulin autoantibodies and protection from diabetes with subcutaneous insulin B:9-23 peptide without adjuvant. Ann N Y Acad Sci 2002;958:224-227. (Pubitemid 34592232)
42. Fousteri G, Dave A, Bot A, Juntti T, Omid S, von Herrath M: Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma. Diabetol 2010;53:1958-1970.
43. Daniel C, Weigmann B, Bronson R, von Boehmer H: Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. J Exp Med 2011; 208:1501-1510.
44. Peakman M, von Herrath M: Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 2010;59:2087-2093.
45. Mordes JP, Cort L, Norowski E, Leif J, Fuller JM, Lernmark A, Greiner DL, Blankenhorn EP: Analysis of the rat Iddm14 diabetes susceptibility locus in multiple rat strains: identification of a susceptibility haplotype in the Tcrb-V locus. Mamm Genome 2009;20:162-169.
46. Liu Z, Cort L, Eberwine R, Herrmann T, Leif JH, Greiner DL, Yahalom B, Blankenhorn EP, Mordes JP: Prevention of type 1 diabetes in the rat with an allele-specific anti-T-cell receptor antibody: Vbeta13 as a therapeutic target and biomarker. Diabetes 2012;61:1160-1168. Diseases